MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The Healthcare practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the North American biopharmaceuticals market to be held on Thursday, March 5, 2009 at 10:00 a.m. PST.
The biopharmaceutical industry has witnessed healthy growth and is experiencing several notable trends, such as the increased use of contract manufacturing organizations and the targeting of biotechnology companies for mergers and acquisitions by pharmaceutical companies or other biotechnology companies. In addition, this industry faces issues that are immersed in heated debate, such as the approval pathway of biosimilars.
This briefing will benefit strategic planners, business development managers, research professionals, marketing managers, and those who are considering entering this dynamic market. Highlights of the briefing include an analysis of overall market trends, general market sizing, and a look at selected issues.
"One of the hot topics in the biopharmaceutical market is the ethical debate surrounding the research and use of embryonic stem cells," notes Frost & Sullivan Research Analyst Katheryn Symank. "This issue is immersed in both political and ethical controversy. Some argue that the use of human embryonic stem cells is unethical while others support their use because of the potential medical good to the population."
To participate, please email Stephanie Ochoa, Corporate Communications, at email@example.com with the following information: your full name, title, company name, company te
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved